Sermorelin vs tesamorelin: one is an approved medicine for one condition, the other's approved product left the market in 2008, and no trial has compared them

Same target, different situations. Both are analogues of growth hormone-releasing hormone and both act on the same pituitary receptor. Sermorelin is the natural fragment, GHRH 1-29. Tesamorelin is that fragment with a chemical modification that makes it last longer.

Tesamorelin is an approved medicine, since 2010, for one condition: reducing excess visceral abdominal fat in people with HIV-associated lipodystrophy. That approval rests on a 412-person randomised trial and pooled phase 3 data.

Sermorelin's approved product left the United States market in 2008. It was approved in 1990, is listed as both a diagnostic agent and a treatment, and is no longer marketed. Every sermorelin prescription written today is a compounded preparation with no approved label behind it.

No trial has compared them. The only published studies naming both are anti-doping assays, which exist because both are on the World Anti-Doping Agency's prohibited list.

Combining them adds overlap, not effect. Two analogues of the same hormone at the same receptor compete for the same thing.

The discontinuation is the part that changes how everything else should be read. A compounded preparation is made to order by a pharmacy; it has no approved label, no manufacturer-run trials behind that specific preparation, and no regulator has assessed its potency, purity or shelf life. That is not the same as being unapproved, and it is not the same as being approved. The clinic pages that rank for this query describe sermorelin as FDA approved, which was true, and leave 2008 out.

Tesamorelin's approval is narrow in a different way. It is an approved medicine, but for one population, people with HIV on antiretroviral therapy who have accumulated visceral fat. Every other use discussed online, general fat loss, liver fat outside HIV, anti-ageing, is off-label, and the trials behind the approval did not study those populations.

There is no randomised comparison of sermorelin and tesamorelin. There is no cohort comparing them. The comparison that the clinic pages make is constructed from each compound's separate literature, and those literatures are not comparable, because they were produced decades apart in different populations for different endpoints.

What does name both, in this record's ledger, is a run of analytical chemistry papers: methods for detecting growth hormone-releasing hormone analogues in urine and blood. They exist because both compounds are prohibited in sport, and they mention sermorelin and tesamorelin the way a metal detector's manual mentions coins.

Five of this page's studies are that kind of paper. They are kept in the ledger because they are the honest answer to what has been published about the two together, and they are labelled with what they are.

Two things follow. The first is that tesamorelin's evidence is recent, large and aimed at one endpoint that it hits repeatedly. The second is that sermorelin's own evidence is old and aimed at a different question entirely, whether a releasing hormone could replace growth hormone in deficient children, and that the modern cognition trial used the 1-29 fragment rather than the marketed product.

Nothing in either column supports the uses these compounds are actually sold for. There is no trial of either for general body composition in healthy adults, for sleep, for recovery or for ageing.

The figures that circulate for compounded sermorelin are not in this table because no trial set them. That is the same boundary this site applies everywhere: a dose appears when a study or a label gave it.

The once-daily versus twice-daily difference is the practical consequence of the chemistry. Tesamorelin's modification slows its breakdown, which is why a single daily injection was enough in trials that ran for a year.

For tesamorelin the answer comes from trials of hundreds of people over a year. Injection-site reactions are the most consistent finding: in the liver trial, more localised injection-site complaints than placebo, none judged serious. Glucose is the effect that gets watched, because growth hormone raises blood sugar, and the pooled phase 3 analysis reported no clinically meaningful change in glucose parameters, while the 2024 subgroup found hyperglycaemia no more common than placebo. Fluid retention, joint pain and carpal tunnel symptoms are the class effects of raising growth hormone, and a 2025 pharmacovigilance study in the tesamorelin record specifically examined carpal tunnel attributed to medication.

For sermorelin there is no equivalent body of evidence for how it is used now. The paediatric trials reported on children given a different preparation for a different reason, decades ago. A compounded product has no adverse-event reporting behind that specific preparation. The honest statement is that its side effects are presumed to be the class effects, and that presumption has not been tested at any scale in the population using it.

Both raise IGF-1, which is the intended effect and the one to monitor. In the cognition trial, IGF-1 rose 117% while staying within the physiological range.

Nothing has been studied, and the pharmacology argues against it. Both compounds bind the same receptor on the same pituitary cells to produce the same pulse of growth hormone. Giving both does not recruit a second pathway; it puts two agonists in front of one receptor, where the effect is bounded by how much hormone the pituitary can release and by the feedback that shuts the process down.

That is different from combining a releasing hormone with a ghrelin-receptor agonist such as ipamorelin, which acts on a separate receptor and is the combination the market actually promotes. Even there, the evidence is about each component rather than the pair.

Related comparisons on this site: ipamorelin vs tesamorelin and ipamorelin vs sermorelin.

Growth hormone-releasing hormone is made in the hypothalamus and tells the pituitary to release growth hormone in pulses. Its biological activity lives in the first 29 amino acids, which is what sermorelin is: GHRH 1-29, the natural sequence, and therefore quickly broken down by the enzyme that clears it.

Tesamorelin is the same 44-amino-acid hormone with a fatty acid group attached at one end, which blocks that enzyme. The result lasts longer in the blood, which is why it works as a once-daily injection while the natural fragment does not.

Both raise growth hormone and, downstream, IGF-1, and both depend on a pituitary that still works, which is the argument usually made for releasing analogues over growth hormone itself: the pulse is shaped by the body's own feedback rather than imposed on it.

Each compound has its own record: sermorelin and tesamorelin.

Supported: tesamorelin reduces visceral and liver fat in people with HIV, repeatedly and in trials designed to measure it; it is approved for that; it is tolerated over a year with injection-site reactions as the main complaint. Sermorelin raises growth hormone and IGF-1, and the GHRH 1-29 fragment improved height velocity in deficient children and cognition in one modern trial.

Not supported: that either is better than the other for anything, since nothing has compared them; that tesamorelin's results in HIV-associated visceral fat transfer to healthy adults seeking fat loss; that compounded sermorelin performs like the product studied in the 1980s; that combining them adds anything; that either is a growth hormone substitute for a use neither was tested for.

The framing the ranking pages use, visceral fat versus anti-ageing, is a marketing division rather than an evidential one. The evidential division is that one of these compounds has been studied for a specific thing in this decade and the other has not.

1. Calling sermorelin FDA approved without saying it was withdrawn. It was approved in 1990 and the product left the US market in 2008; what is prescribed now is compounded.
2. Reading tesamorelin's approval as general. It is approved for visceral fat in HIV-associated lipodystrophy, and its trials enrolled that population only.
3. Treating the two literatures as comparable. One is 1980s paediatric endocrinology, the other is modern HIV metabolic medicine.
4. Assuming a head-to-head exists. The studies naming both are methods for detecting them in doping control.
5. Stacking them. Two agonists at one receptor overlap; the pituitary's output and its feedback set the ceiling.
6. Quoting compounded dosing as if it were a protocol. No trial set those figures, and this page does not reproduce them.